Related Experiment Videos
Treatment failure in endometrial carcinoma
T W Burke1, P B Heller, J E Woodward
1Department of Obstetrics and Gynecology, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland.
Obstetrics and Gynecology
|January 1, 1990
Summary
Endometrial carcinoma survival rates vary significantly by stage and tumor grade. Advanced stages and unfavorable subtypes show poor response to conventional treatments, necessitating new therapeutic strategies.
Area of Science:
- Gynecologic Oncology
- Clinical Oncology
- Pathology
Background:
- Endometrial carcinoma is a curable gynecologic malignancy.
- Prognostic variables include clinical stage, grade, and myometrial invasion depth.
Purpose of the Study:
- To examine the clinical course and survival outcomes of endometrial carcinoma patients.
- To evaluate prognostic factors and treatment effectiveness.
Main Methods:
- Retrospective analysis of 520 endometrial carcinoma patients treated between 1960 and 1982.
- Life table analysis for 5-year survival rates by stage (Ia-IV).
- Comparison of survival based on tumor grade and histologic subtype.
Main Results:
- 5-year survival rates: Stage Ia (89%), Ib (92%), II (77%), III (27%), IV (0%).
- Decreased survival observed for higher grades (2-3) and unfavorable subtypes (papillary endometrioid, serous papillary, clear-cell).
- Recurrence occurred in 7.3% of patients; pelvic recurrences had better salvage rates with radiotherapy than distant failures.
Conclusions:
- Advanced stage and unfavorable histology significantly impact endometrial carcinoma prognosis.
- Conventional therapies are largely ineffective for advanced or persistent disease.
- Combined-modality and systemic adjuvant therapies require prospective evaluation in high-risk groups.